← Back to Search

Cannabinoid Receptor Agonist

EHP-101 low dose twice a day for Systemic Sclerosis

Phase 2
Recruiting
Research Sponsored by Emerald Health Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 85 and day 113
Awards & highlights

Study Summary

This trial is testing a new drug for safety and effectiveness in treating a skin condition called systemic sclerosis.

Eligible Conditions
  • Systemic Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 85 and day 113
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 85 and day 113 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of Treatment Emergent Adverse Events
Secondary outcome measures
Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis
Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index
Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted
+3 more
Other outcome measures
Change from baseline of EHP-101 compared to placebo in 5 dimensions Itch Score
Change from baseline of EHP-101 compared to placebo in Functional Assessment of Chronic Illness Therapy: Fatigue
Change from baseline of EHP-101 compared to placebo in Patient-Reported Outcomes Measurement Information system-29 Short
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: EHP-101 low dose twice a dayExperimental Treatment1 Intervention
Group II: EHP-101 low dose once a dayExperimental Treatment1 Intervention
Group III: EHP-101 high dose twice a dayExperimental Treatment1 Intervention
Group IV: EHP-101 high dose once a dayExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Emerald Health PharmaceuticalsLead Sponsor
2 Previous Clinical Trials
154 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
2020. "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04166552.
All > Scleroderma Research Foundation
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top